RT Journal Article
SR Electronic
T1 SARS-CoV-2 lethality decreased over time in two Italian Provinces
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.23.20110882
DO 10.1101/2020.05.23.20110882
A1 Maria Elena Flacco
A1 Cecilia Acuti Martellucci
A1 Francesca Bravi
A1 Giustino Parruti
A1 Alfonso Mascitelli
A1 Lorenzo Mantovani
A1 Lamberto Manzoli
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.23.20110882.abstract
AB Background Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence is yet available. This retrospective cohort study aimed to evaluate whether SARS-CoV-2 case-fatality rate decreased with time, adjusting for main potential confounders.Methods and findings We included all SARS-CoV-2 infected subjects diagnosed in Ferrara and Pescara provinces, Italy. Information were collected from local registries, clinical charts, and electronic health records. We compared the case-fatality rate of the subjects diagnosed during April and March, 2020. We used Cox proportional hazards analysis and random-effect logistic regression, adjusting for age, gender, hypertension, type II diabetes, major cardiovascular diseases (CVD), chronic obstructive pulmonary diseases (COPD), cancer and renal disease. The sample included 1946 subjects (mean age 58.8y; 45.7% males). 177 persons deceased, after a mean of 11.7 days of follow-up. From March to April, the case-fatality rate significantly decreased in the total sample (10.8% versus 6.0%; p<0.001), and in any subgroup of patients. Large reductions of the lethality were observed among the elderly (from 30.0% to 13.4%), and subjects with hypertension (23.0% to 12.1%), diabetes (30.3% to 8.4%), CVD (31.5% to 12.1%), COPD (29.7% to 11.4%), and renal disease (32.3% to 11.5%). In April, the adjusted hazard ratio of death was 0.42 (95% Confidence Interval: 0.29-0.60). The mean age of those who died substantially increased from March (77.9±10.8y) to April (86.9±7.7y).Conclusions In this sample, SARS-CoV-2 case-fatality rate decreased considerably over time, supporting recent claims of a substantial improvement of SARS-CoV-2 clinical management. The findings are inevitably preliminary and require confirmation.Author summaryWhy was this study done?Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence is yet available.What did the researchers do and find?We carried out a retrospective cohort study on 1946 SARS-CoV-2 infected subjects from two Italian provinces, evaluating the potential variation of the case-fatality rate over time.From March to April, in both univariate and multivariable analyses, SARS-CoV-2 case-fatality rate significantly and substantially decreased, overall and in any subgroup of subjects.What do these findings mean?The therapies and clinical management of SARS-CoV-2 infected subjects might have substantially improved over time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Emilia Romagna Region.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available from the corresponding author upon request.COPDchronic obstructive pulmonary diseaseCOVID-19coronavirus disease 2019CVDcardiovascular diseaseHRhazard ratioRT-PCRreverse transcription polymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 2SDOhospital discharge abstract (scheda di dimissione ospedaliera)